Buy Blincyto in India — Price & Availability

What is Blincyto used for?

Blincyto (blinatumomab) is a CD19-directed CD3 bispecific T-cell engager (BiTE®). It binds CD19 on the surface of B-lineage cells and CD3 on T cells at the same time, bringing the patient’s own T cells into close contact with the leukaemia cells so the T cells can destroy the CD19-positive cancer cells.

It is approved for adults and children one month of age and older with CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL), including:

• Philadelphia chromosome–negative B-cell precursor ALL in the consolidation phase of
• multiphase chemotherapy.
  Minimal residual disease (MRD)-positive B-cell precursor ALL — MRD ≥ 0.1% in first or second complete remission.
• Relapsed or refractory B-cell precursor ALL (Philadelphia chromosome–positive or –negative disease).

It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist or haematologist experienced in treating ALL.

Recommended dosage:
Blincyto is given as a continuous intravenous infusion delivered through a programmable infusion pump — never as an IV push or bolus. Each infusion bag may be prepared to run over 24 hours, 48 hours, 72 hours, 96 hours, or 7 days, depending on the preparation used.
Dosing is weight-based and is decided by the treating doctor:
Patients weighing 45 kg or more receive a fixed dose, typically starting at 9 mcg/day and escalating to 28 mcg/day.
Patients weighing less than 45 kg receive a body-surface-area–based dose, typically starting at 5 mcg/m²/day and escalating to 15 mcg/m²/day (not exceeding the adult 28 mcg/day dose).

A treatment cycle generally consists of 28 days of continuous infusion followed by a treatment-free interval, repeated for the number of cycles prescribed. Hospitalisation or close supervision is recommended for the early days of the first cycle. The treating doctor always determines the exact dose, schedule, and number of cycles.

Boxed warning: Blincyto carries a boxed warning for cytokine release syndrome (CRS) and serious neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), both of which may be severe, life-threatening, or fatal. Treatment may be interrupted or stopped, and corticosteroids given to manage these effects.

• Cytokine release syndrome (CRS): may cause fever, headache, nausea, weakness, low blood pressure, and abnormal liver tests; patients are monitored closely, especially early in treatment.
• Neurological toxicities (including ICANS): may include seizures, confusion, disorientation, difficulty speaking, tremor, or loss of balance; report any such symptoms immediately.
• Infections: Blincyto can increase the risk of serious infections; report fever, chills, or signs of infection promptly.
• Infusion reactions: patients are monitored during the infusion; pre-medication may be given.
• Low blood counts: neutropenia, anaemia, and thrombocytopenia can occur and are monitored with regular blood tests.
• Other precautions: pancreatitis, effects on the ability to drive or operate machinery, and the need to avoid live vaccines around treatment.
• Pregnancy and breastfeeding: Blincyto may harm an unborn baby; effective contraception is advised, and breastfeeding is not recommended during and for a period after treatment.

Common side effects:
Frequently reported effects include fever (pyrexia), infusion-related reactions, headache, infections, febrile neutropenia, low white cells, low platelets, anaemia, nausea, diarrhoea, and musculoskeletal pain. This is not a complete list — refer to the full prescribing information and your treating doctor.

Patients in India can legally access Blincyto through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
• Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Cold-chain import & delivery — Blincyto is sourced and shipped under validated 2–8 °C conditions to the patient or treating hospital.

What documents are required to import Blincyto? 

Blincyto (Blinatumomab) injection can be imported by patients or government hospitals on behalf of patients. The following documentation is required to import the product: 

• A valid prescription from a qualified doctor. 
• Patient’s diagnostic reports. 
• Patient’s ID proof (issued by the Government of the respective country). 

How is the order confirmed? 

The order will be confirmed only after the receipt of: 

• A valid prescription from a doctor. 
• Import permit if applicable. 

Is Blincyto available worldwide? 

Blincyto (Blinatumomab) injection is a prescription pharmaceutical drug that legally requires a medical prescription for dispensation. 

Indian Pharma Network (IPN) facilitates the import of critical medications like Blincyto (Blinatumomab) globally, ensuring the named patient supply (NPS). IPN is the facilitator that provides essential support for: 

• Availability of Blincyto (Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka). 
• BLINCYTO Available in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc
• Determining Medicine Price. 
• Sourcing genuine and reliable sources from the USA, Canada, Europe, and Australia. 
• Ensuring 100% transparency. 

Blincyto (Blinatumomab) injection can be made available to patients, doctors, and hospitals in various countries across the globe. The order will be confirmed only after receiving a valid prescription from the doctor and, if required, an import permit. 

Indian Pharma Network (IPN) can facilitate the supply of Blincyto (prescription medicine) to locations worldwide while adhering to legal requirements (if applicable). 

We assure quality and worldwide delivery as per the buyer’s  specifications. 

Because Blincyto is not sold on the open market in India, there is no fixed MRP. The Blincyto cost in India depends on a few factors at the time of import:

• The number of 35 mcg vials required, which is based on the patient’s body weight (or body surface area), the prescribed dose, the infusion duration per bag, and the number of treatment cycles.
• The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Cold-chain logistics, insurance, and any applicable customs duties or import permit costs.

Get a transparent quote:

We provide a written quotation covering Blincyto price, logistics, and delivery timeline once a valid prescription is shared. Request your Blincyto quote →

Blincyto is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid prescription, in line with applicable regulations.

Indian Pharma Network sources Blincyto from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, the lyophilized Blincyto vials and the IV Solution Stabilizer vials require cold-chain handling at 2 °C–8 °C throughout transit, kept in the original carton, protected from light, and never frozen. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Blincyto can be made available to patients, doctors, and hospitals across major cities in India,including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

Regulatory approval status

Blincyto first received US FDA approval on 3 December 2014 (accelerated approval) for Philadelphia chromosome–negative relapsed or refractory B-cell precursor ALL. The FDA later granted regular approval and expanded the indication to include Philadelphia chromosome–positive disease (2017), added the MRD-positive indication (2018), and approved use in the consolidation phase of Philadelphia chromosome–negative B-cell precursor ALL (14 June 2024). It received a conditional marketing authorisation in the European Union on 23 November 2015, later converted to a standard authorisation. Blincyto is approved in several markets, including the United States, the European Union, Canada, Japan, China, and others. As of the current publicly available information, Blincyto is not commercially marketed in India, which is why the Named Patient route is used.